Every cancer alliance manager knows the moment. A triage tool has performed well in one trust, the evaluation is favourable, the clinical lead is enthusiastic, and then the project reaches the point where someone must pay for staff training, pathway redesign and the hours needed to run it. The pilot money has ended. The business case waits for next year's planning round, and by then the momentum has gone.
The fourth round of the NHS Cancer Programme Innovation Open Call, which opened on 19 October and is delivered through SBRI Healthcare, is built around that moment. It offers funding of up to £5 million, and its structure deserves more attention than its headline figure. One route provides up to £3 million over a maximum of 24 months for market-ready innovations, requiring a UK or EU organisation with a demonstrable NHS partner in England and an independent evaluation partner. The other provides up to £5 million for integrated care boards working with Cancer Alliances, for innovations already shown to improve patient outcomes at a favourable cost. That money is released through an outcomes-based, matched funding agreement, over the first 24 months of a project lasting up to 36.
The timing matters. The NHS is working towards meeting cancer waiting time standards by March 2029, and towards an ambition that three quarters of people diagnosed with cancer will be cancer free, or living well, five years on by 2035. Neither goal can be reached through extra workforce alone, and the call acknowledges as much. Its examples focus on managing demand and releasing capacity: triage in primary and community care that avoids unnecessary referrals onto urgent suspected cancer pathways, AI tools that sort referrals already on those pathways, decision support, and ambient AI that returns clinicians' time from documentation to patients. Productivity gains of this kind are modest in any single clinic and considerable across a national system.
The matched funding arrangement is the sharper policy signal. Innovation in the NHS has rarely lacked pilots. It has lacked a mechanism that pays for the organisational change a pilot quietly depends upon. By describing its approach as funding the change as well as the technology, the programme recognises that a diagnostic tool without redesigned workflows is a licence waiting for a purpose. Requiring ICBs to put in matching money gives commissioners a stake in the result, and the requirement for evidence of outcomes and cost effectiveness keeps the spending disciplined. For boards under financial strain, that combination offers a route to adopt something proven without carrying the whole risk.
The interoperability conditions carry equal weight. Successful innovations must work with electronic patient records, the NHS App, the federated data platform and the Cancer360 pathway management tool. Suppliers receive a clear specification, which is useful. Trusts gain some protection against the familiar problem of a promising system that cannot talk to anything else. The requirement also shows where central policy is heading, towards a connected data architecture that new tools are expected to join rather than circumvent.
There are practical points for leaders to weigh. The deadline is 1 December at 13:00, with contracts due to start by 30 April 2027, so partnerships between ICBs, Cancer Alliances and suppliers need to form within weeks. Integration work is rarely quick, and a 24-month funded window will test how fast real deployment can move. Boards will also need to identify their matched contribution in a tight financial year. These are manageable conditions, and they favour applicants who have already done the groundwork on clinical engagement and data governance.
For patients, the prize is concrete. Better triage means fewer people waiting on pathways that were never right for them, which frees diagnostic capacity for those who need it urgently. Earlier detection through novel screening and case-finding tools shifts diagnosis to a stage at which treatment is more effective.
The programme will be judged by what happens after the funding period. If the 36-month projects continue to run once the grant has gone, with the new workflows absorbed into ordinary commissioning, the open call will have shown how proven innovation can become routine practice in NHS cancer care.
